We are proudly a Ukrainian website. Our country was attacked by Russian Armed Forces on Feb. 24, 2022.
You can support the Ukrainian Army by following the link: https://u24.gov.ua/.
Even the smallest donation is hugely appreciated!
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cardiolipin antibody.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Schlame, Michael, Ivan Haller, Lisa Sammaritano, and Thomas Blanck. "Effect of Cardiolipin Oxidation on Solid-Phase Immunoassay for Antiphospholipid Antibodies." Thrombosis and Haemostasis 86, no. 12 (2001): 1475–82. http://dx.doi.org/10.1055/s-0037-1616751.
SummaryDiagnostic assays for antiphospholipid antibodies are routinely performed on microtitre plates coated with cardiolipin. Here we show that contact between cardiolipin and NUNC-Immuno® plates leads to extensive oxidation, generating a series of peroxy-cardiolipins which were identified by electrospray ionization mass spectrometry. To investigate the impact of oxidation on the antibody assay, cardiolipin was resolved into 12 molecular species, including oxidized species and non-oxidized species with different degrees of unsaturation. All 12 species reacted under anaerobic conditions with serum from patients with primary antiphospholipid syndrome. Immune reactivity was similar for tetralinoleoyl-cardiolipin, trilinoleoyl-oleoyl-cardiolipin, and peroxycardiolipins, but somewhat lower for tristearoyl-oleoyl-cardiolipin. Oxidative treatment of cardiolipin with air, cytochrome c, or Cu2+/tert-butylhydroperoxide, either before or during the assay, did not enhance immune reactivity. Similar results were obtained with a monoclonal IgM from lupus-prone mice, that binds cardiolipin in the absence of protein cofactors. We conclude that the solid-phase assay for antiphospholipid antibodies can be supported by various oxidized and nonoxididized molecular species of cardiolipin.
3
Costello, P. B., and F. A. Green. "Cholesterol effects on the interaction of cardiolipin with anti-cardiolipin antibody." Biochimica et Biophysica Acta (BBA) - Biomembranes 896, no. 1 (January 1987): 52–56. http://dx.doi.org/10.1016/0005-2736(87)90355-5.
Harris, E. Nigel, and GrahamR V. Hughes. "STANDARDISING THE ANTI-CARDIOLIPIN ANTIBODY TEST." Lancet 329, no. 8527 (January 1987): 277. http://dx.doi.org/10.1016/s0140-6736(87)90099-7.
D'Agati, V., C. Kunis, G. Williams, and G. B. Appel. "Anti-cardiolipin antibody and renal disease: a report three cases." Journal of the American Society of Nephrology 1, no. 5 (November 1990): 777–84. http://dx.doi.org/10.1681/asn.v15777.
Anti-cardiolipin antibodies have been linked to recurrent arterial and venous thrombosis in multiple organs. We present a biopsy-documented report of thrombotic renal disease apparently attributable to circulating anti-cardiolipin antibodies. One patient had primary anti-cardiolipin syndrome, one had mild SLE, and the third had a mild lupus-like syndrome. All three patients had a clinical course dominated by repeated multi-organ system thrombosis. Renal biopsy disclosed thrombosis at the level of the glomerular capillaries, arterioles, and interlobular arteries--similar to that described in other thrombotic microangiopathies. Renal thrombosis was not associated with active endocapillary proliferative lupus nephritis, suggesting a mechanism independent of subendothelial immune deposit injury. Renal presentation was variable, ranging from asymptomatic mild proteinuria to nephrotic-range proteinuria, renal insufficiency, and hypertension.
8
SUMITA, TAKAYUKI. "V region gene of anti-cardiolipin antibody." Japanese Journal of Clinical Immunology 16, no. 6 (1993): 546–54. http://dx.doi.org/10.2177/jsci.16.546.
Abdolreza, Abdolreza, Mohammad Shojaie, Samira Dana, and Abdoulhossain Madani. "Anti-Cardiolipin Antibody in Acute Myocardial Infarction." American Journal of Immunology 6, no. 1 (January 1, 2010): 11–14. http://dx.doi.org/10.3844/ajisp.2010.11.14.
Kilpatrick, David C., Rose E. B. Haining, and Steven S. K. Smith. "Are cardiolipin antibody levels elevated in endometriosis?" Fertility and Sterility 55, no. 2 (February 1991): 436–37. http://dx.doi.org/10.1016/s0015-0282(16)54144-2.
Dissertations / Theses on the topic "Cardiolipin antibody":
1
Gatenby, Paul, Gytis Danta, Roger Tuck, Colin Andrews, and Carolyn Hawkins. "Cerebrovascular disease associated with antiphospholipid antibodies: more questions than answers." Master's thesis, BioMed Central, 2006. http://hdl.handle.net/10440/104.
Neurological syndromes occur in a significant number of patients with antiphospholipid antibodies. The
optimal management for these patients however remains uncertain.
Our study is a descriptive analysis looking retrospectively at 45 patients who presented to the principal
tertiary referral centre in the Australian Capital Territory, with either cerebral arterial or venous
thrombosis for which there was no obvious cause for their presentation when initially reviewed. The
diagnosis was based on the clinical findings made by one of three neurologists attached to our centre.
Radiological findings and the presence of either IgM or IgG anticardiolipin antibodies, IgG anti-beta-2
glycoprotein 1 antibodies or a lupus anticoagulant were then documented.
In this group of patients three subgroups were identified:
1. Individuals that fulfilled the Sapporo Classification Criteria
2. Individuals with transiently positive antiphospholipid antibodies and
3. Individuals with persistently low positive antiphospholipid antibodies.
The most interesting of these three groups are those individuals with transiently positive antiphospholipid
antibodies. A potential cause for presentation was identified in only one patient of this group with
documented infective endocarditis and bacteraemia. Comparison with the other two groups suggested
that there was little in terms of clinical presentation, radiological findings or intercurrent risk factors for
thrombotic disease to distinguish between them. With disappearance of antiphospholipid antibodies, the
individuals within this group have not had further thrombotic events.
Our observations emphasise the problems that continue to exist in relation to the occurrence of
cerebrovascular disease in the context of antiphospholipid antibodies and the optimal management of
these stratified groups. Our findings also raise an as yet unanswered question as to the signficance of these
transiently positive antiphospholipid antibodies. In the absence of significant intercurrent risk factors our
findings would suggest that in the group we describe that they are likely to be of clinical significance.
Book chapters on the topic "Cardiolipin antibody":
1
Bhasker, Nilam. "Interrelation between Recurrent Pregnancy Loss and Antiphospholipid: A Clinico-Diagnostic Perspective." In Protein Detection. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.100125.
Recurrent pregnancy loss, one of the crucial reproductive health concerns affecting 6% of couples. Clinically recognized pregnancy loss is familiar, occurring in approximately 15–25% cases of pregnancy. The most common cause of recurrent pregnancy loss is cytogenetic anomaly, antiphospholipid antibody, metabolic and hormonal disorders. However, approximately 50% cases of recurrent pregnancy loss remain unexplored. Recurrent pregnancy loss is correlated with specificity of antiphospholipid like anti-β2-glycoprotein-I antibodies, lupus anticoagulant, anti-cardiolipin antibodies, and anti-phosphatidylserine. aPL inhibits the release of human chorionic gonadotropin (HCG) hormone from placenta, trophoblast growth, migration, and cell adhesion while induce the inflammatory response in earlier pregnancy. Some clinical studies reported that occurrence of antiphospholipid during recurrent pregnancy loss is uncommon. In this time line article, we are focusing on the role of antiphospholipid in the recurrent pregnancy loss and clinico-diagnostic against recurrent pregnancy loss.
Conference papers on the topic "Cardiolipin antibody":
1
Cunningham-Rundles, C., J. Bussel, and A. Lipscombs. "CHANGES IN ANTI-CARD10LIPIN ANTIBODY TITER IN SERA OF I TP PATIENTS AFTER TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643924.
Antibodies to cardiolipin have previously been demonstrated in the sera of patients with idiopathic thrombocytopenia purpura (ITP). We questioned whether the levels of anti-cardiolipin in the sera of patients with ITP would be altered after treatment with intravenous immunoglobulin (IVGG). Using flexible polyvinyl chloride microtiter plates coated with bovine cardiolipin, we measured IgG and IgM anti-cardio1ipin levels by ELISA before and at multiple intervals during and after IVGG treatment for 17 patients who had ITP. We found that within 7-10 days of treatment, 16 of 17 patients had further increases of IgG anti-cardiolipin antibody. This is probably due to the infusion of IVGG concentrates, which we found contained substantial amounts of IgG anti-cardio1ipin. Increases in platelet counts had significant correlation with increased IgG anti-cardio1ipin (p>0.01), presumably also due to the infusion of IVGG. Surprisingly, 16 of 17 patients had a marked increase in serum levels of IgM anti-cardiolipin 7-10 days post IVGG treatment. Since IVGG does not contain IgM anti-cardiolipin and our assay is specific for this isotype, this antibody represents de novo synthesis. We previously reported and have also confirmed here, that 16 of these 17 patients had increased serum IgM levels after IVGG treatment. The increase in serum IgM anti-cardio1ipin antibody may explain part of the increased total serum IgM observed. IVGG has been believed to be potentially suppressive of various immunologic activities; our data shows that immunologic stimulation also occurs. The biologic effect of increased serum IgG and IgM anti-cardiol ipin after IVGG treatment in ITP, particularly since cardiolipin may be a constituent of platelet membranes, is still uncertain.
2
Criel, A., B. Gilbert, A. Van Hoof, M. Hidajat, and A. Louwagie. "COMPARISION OF THE DETECTION OF LUPUS ANTICOAGULANTS USING THREE DIFFERENT METHODS AND THE PRESENCE OF ANTI-CARDIOLIPIN ANTIBODIES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644233.
Lupus anticoagulant (LAC) is an antibody directed against phospholipids which prolongs in vitro clotting assays. Several detection methods have been described; however all give some different results. Recently ELISA and RIA assays have been developed which detect IgG and IgM anti-cardiolipin antibodies. The aim of our study was to compare three different LAC tests with an ELISA anti-cardiolipin test. The tests used were : kaolin clotting time (KCT or Exnertest), tissue thromboplastin inhibition test (TTI or Schleider test), activated partial thromboplastin time using a 50, 100, 200 fold dilution of the phospholipid preparation (APTT dilution test), and an IgG and IgM anti-cardiolipin ELISA test. 114 samples of patients suffering from diseases known to be accompanied with LAC antibodies (auto-immune diseases, recurrent abortion, thromboembolism, etc.) were studied. Positivity with one of the tests was found in 45 patients (39%). Patients with the diagnosis of SLE or otherimmune diseases showed the highest positivity (56%) whereas those with thromboembolism, recurrent abortion etc. were only positive in 27%.Among these 45 positive patients the TTI was positive in 41 cases (91 %);however in 10 cases (24 %) this was the only positivity found. The KCT test and the APTT dilution test were both positive in 18 cases (40 %). Anti-cardiolipin antibodies were found in 21 patients (47 %): IgG only in 12 (27 %), IgM only in 5 (11 %), both IgG and IgM in 2 (4 %); in 19 of these 21 patientsthe TTI was also positive.In our study the TTI test seems to be the most sensitive test but possibly also the test with the highest aspecific positivities. IgG and IgM anti-cardiolipin antibodies were less frequently found than expected.
3
Harris, EN, RA Asherson, E. Baguley, M. Ridley, and GRV Hughes. "A STANDARD ANTI-CARDIOLIPIN (aCL) TEST: USEFULNESS IN IDENTIFICATION OF THE ANTI-PHOSPHOLIPID SYNDROME." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644235.
Some, but not all, patients with the lupus anticoagulant and anti-cardiolipin antibodies are prone to thrombosis, fetal loss and thrombocytopenia. It will be important to identify the particular sub-group of patients with anti-phospholipid (aPL) antibodies most subject to these clinical disorders. A preliminary study has shown that the level of IgG aCL antibody is predicitive for thrombosis, fetal loss, and thrombocytopenia but it will be difficult to substantiate (or refute) these findings unless there is a uniform system to measure aCL antibody levels.Five test sera with defined IgG and IgM aCL levels are currently available to laboratories wishing to standardise the aCL test. The concentrations of aCL in these sera cover the full sensitive range of aCL solid phase assays. Using these. 5 test sera to calibrate our assay system, sera from 3000 patients were analysed: 1400 healthy adults and 1600 consecutive patients with autoimmune disorders. All sera from healthy adults had aCL levels below 10GPL (IgG aCL) or below 10MPL (IgM aCL) units. Of the 1600 autoimmune patients, 115 had levels above 5 GPL and/ or 5MPL units. More than 2/3 of patients with IgG aCL levels above 20 GPL units (30 patients) had thrombosis or fetal loss, but the frequency of these disorders decreased in the 10-20 GPL and 5-10 GPL unit groups. Of the 9 patients with IgM aCL levels above 15 MPL units, 6 had thrombosis or fetal loss.The availability of reference sera to measure IgG and IgM aCL antibody levels may better enable multicenter studies to be performed. A relatively uniform system of measurement may also enable easier identification and management of patients with the anti-phospholipid syndrome.
4
Shukla, Mayur, John W. Deutsch, Ellen N. Kersh, and Yetunde F. Fakile. "P1.42 A new magnetic particle-based agglutination assay for anti-cardiolipin antibody detection in syphilis." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.150.
Tran, D., Y. Huang, M. Eltelbany, J. Mikdashi, P. Sandhu, A. Akbaryeh, N. Iloh, and I. Bakhtawar. "A Rare Association Between Recurrent Episodes of Pulmonary Embolism and Antisynthetase Syndrome with Negative Anti-Cardiolipin Antibody." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1370.
Triplett, D. A., J. T. Brant, K. Musgrave, and C. A. Orr. "RELATIONSHIP BETWEEN LUPUS ANTICOAGULANTS AND ANTIBODIES TO PHOSPHOLIPID." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643657.
The relationship of lupus anticoagulants (LA's) to antibodies (IgG and IgM) to cardiolipin (CL), phosphatidylserine (PS), phosphatidylinositol (PI) and phosphatidic acid (PA), detected by an enzyme linked immunoassay, was examined in a series of 100 patients with well characterized LA's. 73% of patients demonstrated antibodies to one or more phospholipids; 62% were positive for CL, 57% were positive for PS, 57% were positive for PI, and 51% were positive for PA. Of the samples with antibodies to phospholipid, 32% had IgG type antibody only, 16% had IgMonly, and 52% had both IgG and IgM antibodies. Of the 100 patients,19% had a history of thrombosis, 8% had ahistory of spontaneous abortion, and 6% had a history of seizure disorder. These complications occurred in the presence (61%) and absence (39%) of detectable phospholipid antibodies. Drug-related LA's were observed in 34 patients; of these 74% were positivefor antiphospholipid antibodies and 24% hada history of thrombosis.The distribution of antibody types with drug-related LA's was similarto the overall group, with 40% IgG only, 8%IgM only and 52% both IgG and IgM These findings indicate that IgG and IgM antibodies to phospholipid are not observed in all patients with lupus anticoagulants, that thrombosis does occur in this population in the absence of detectable antibodies to phospholipid and that drug-related LA's are associated with thrombosis. Furthermore, there appeared to be little relationship between the degree of prolongation of the aPTT and the titer of anti-phospholipid antibody.
7
Cooper, S. M., R. G. Malia, F. E. Preston, S. L. B. Duncan, AR B. Smith, and M. Greaves. "CLINICAL AND LABORATORY FEATURES ASSOCIATED WITH LUPUS ANTICOAGULANT." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644231.
Recent evidence suggests a relationship between the presence of lupus anticoagulant and elevated titres of antibody to cardiolipin. Also an association with thrombotic tendency and with a high incidence of first trimester spontaneous abortion or second and third trimester fetal death has been noted. In order to investigate the relationship between anticardiolipin (aCL) antibodies and coagulation test abnormalities we have studied 12 subjects with systemic lupus erythematosus (SLE),10 with history of venous thrombosis, 30 with unexplained prolongation of clotting times and 34 with a poor obstetric history. Coagulation tests applied were: KCCT using two ’incomplete’ thromboplastin preparations and corrections with 20%/50% normal plasma; one-stage prothrombin time (OSP); dilute Russell’s viper venom time (DRVVT, including the platelet neutralisation procedure) and the heat stability test. IgG and IgM aCL antibody were assayed by enzyme-linked immunosorbent assay as described elsewhere. Abnormalities in more than one coagulation test were detected in 4 subjects with SLE (33%), 4 with thrombosis (40%), 6 with poor obstetric history (18%) and 10 with unexplained prolonged KCCT (33%). The DRVVT was most sensitive to the presence of lupus anticoagulant. Detectable aCL antibody was present in 12 subjects (IgG in 6, IgM in 4, both in 3), including some from each group. 2 had IgG aCL antibody and normal coagulation tests (1 SLE, 1 poor obstetric history). No coagulation or immunological abnormality was detected in 30 healthy non-pregnant and 13 healthy pregnant controls. Our data indicate the requirement for a comprehensive methodological approach for the detection of aCL antibodies/lupus anticoagulant and the clinical importance of such an approach.
8
IZAGUIRRE, C. A., S. DUFF, S. HASHMENT, C. D. SMITH, Q. H. MENG, and J. RAUGH. "HETEROGENEOUS REACTIVITY OF HUMAN MONOCLONAL ANTIPHOSPHOLIPID ANTIBODIES (HMA) WITH ENDOTHELIAL CELLS (EC), PLATELETS AND DNA." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643659.
Antibodies that react with cardiolipin (ACL) and/or have lupus anticoagulant (LA) properties are implicated in the thrombotic diathesis of patients with the antiphospholipid antibody syndromes: recurrent venousand arterial thrombosis, fetal wastage, thrombocytopenia and CNS disease, often associated with systemic lupus erythematosus. We studied a panel of 16 HMA with LA and/or ACL properties (J Biol Chem 261:9672 1986) for their reactivity with platelets (ELISA),DNA (ELISA), with surface antigensonEC (EC-ELISA) and with whole cell EC extracts as detected by western blot and immunoperoxidase (EC-WB). Three control HMA werenonreactive in all assays.Five HMA with LA activity alone did not react with EC. Five of 6 HMA-ACL reacted with EC both on ELISA and WB. All of the HMA-ACL also reacted with DNA and platelets but 4 did not react as LA. Our findings indicate that HMA antiphospholipid antibodies(LA and ACL) appear to be heterogeneous in terms of their spectrum of reactivities, thus, the ACL and LA tests may in some cases recognize antibodies with different properties and perhaps different pathogeneticmechanisms.xs
